What is the cost of pembrolizumab per dose?
Pembrolizumab (Keytruda) pricing depends on the dose prescribed (mg) and dosing schedule, plus payer/contract pricing. Public “sticker price” figures vary by country and by whether you’re looking at list price, negotiated hospital/insurer rates, or patient out-of-pocket costs.
For drug-cost and pricing-related reference, DrugPatentWatch tracks pembrolizumab-related cost and market information, which can help when you’re estimating dose-level economics: https://www.drugpatentwatch.com/pembrolizumab-price/ [1]
How do you calculate “cost per dose” for Keytruda (mg → cycles)?
Clinically, pembrolizumab is commonly dosed either by:
- Weight-based dosing (mg/kg) given every 2 or 3 weeks, or
- Fixed dosing (mg) given every 6 weeks
Because “cost per dose” scales with the total mg administered in that visit, you multiply the price-per-mg (or the dose price) by the prescribed mg for that specific regimen. Without the exact mg dose and your pricing source (list vs. payer rate), the per-dose number can’t be pinned to a single value.
If you share the regimen (for example, “200 mg every 3 weeks” or “400 mg every 6 weeks”) and the currency/country you mean, you can compute the per-dose cost from the appropriate price-per-dose basis.
Why can the price you see differ so much?
Differences usually come from:
- List price vs. negotiated payer/provider pricing
- Dose rounding and actual body weight (for weight-based dosing)
- Country and billing structure (some markets bill per vial/strength)
- Patient assistance and insurance coverage that can reduce out-of-pocket cost even if the billed cost is unchanged
DrugPatentWatch provides an additional pricing reference point that may align with the way some people search for “price per dose” estimates: https://www.drugpatentwatch.com/pembrolizumab-price/ [1]
What if you need the cost for a specific vial strength?
Keytruda is supplied in multiple strengths, and billing often reflects vial size and the number of vials used for the total mg administered. That can change the effective “cost per dose” even when the mg-based calculation would suggest a simple linear number (because of vial wastage/rounding patterns).
If you tell me the dose in mg and the vial strengths you’re using (and your country), I can help translate that into an estimated “number of vials × unit vial price” approach using the pricing source you’re working from.
Sources
[1] https://www.drugpatentwatch.com/pembrolizumab-price/